Scholarlink

Background <p>We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).</p> Methods <p>We studied etanercept-naive participants with RA from four Canadian prospective cohorts who initiated ETA-B or ETA-O (Jan/2015-May/2022). Disease remission was determined using disease activity scales. Sustained remission was defined as at least two consecutive visits in remission within the first 12 months of follow-up. Multivariate Cox regression was used to compare the probability of achieving remission between ETA-B and ETA-O, and multivariate logistic regression was used to assess sustained remission.</p> Results <p>We studied 150 participants with RA (ETA-B: 65.3%). Among 125 participants not in remission at baseline, the median time to first remission was 8.7 months (95% confidence intervals [CI] 5.2–12.1) in the ETA-B group and 14.5 months (95% CI 4.7–18.6) in the ETA-O group. Time to first remission was similar between the groups (log-rank test: <i>P</i>-value = 0.51). Multivariate Cox regression showed no clear difference in first remission between ETA-B and ETA-O (adjusted hazard ratio 1.52, 95% CI 0.68–3.39). Among 125 participants with at least 12 months of follow-up, the prevalence of sustained remission was 19.5% for ETA-B and 21.0% for ETA-O. In multivariate analysis, we did not detect a significant difference in sustained remission between ETA-B and ETA-O (adjusted odds ratio 1.14, 95% CI 0.29–4.87).</p> Conclusion <p>We did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O.</p> Trial registration <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Marina G. Birck,
  • Jessica Boivin,
  • Laura Yan,
  • Nathalie Carrier,
  • Cristiano S. Moura,
  • Walter P. Maksymowych,
  • Gilles Boire,
  • Denis Choquette,
  • Luck Lukusa,
  • Michael Mallinson,
  • Linda Wilhelm,
  • Autumn Neville,
  • Sasha Bernatsky

摘要

Background

We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).

Methods

We studied etanercept-naive participants with RA from four Canadian prospective cohorts who initiated ETA-B or ETA-O (Jan/2015-May/2022). Disease remission was determined using disease activity scales. Sustained remission was defined as at least two consecutive visits in remission within the first 12 months of follow-up. Multivariate Cox regression was used to compare the probability of achieving remission between ETA-B and ETA-O, and multivariate logistic regression was used to assess sustained remission.

Results

We studied 150 participants with RA (ETA-B: 65.3%). Among 125 participants not in remission at baseline, the median time to first remission was 8.7 months (95% confidence intervals [CI] 5.2–12.1) in the ETA-B group and 14.5 months (95% CI 4.7–18.6) in the ETA-O group. Time to first remission was similar between the groups (log-rank test: P-value = 0.51). Multivariate Cox regression showed no clear difference in first remission between ETA-B and ETA-O (adjusted hazard ratio 1.52, 95% CI 0.68–3.39). Among 125 participants with at least 12 months of follow-up, the prevalence of sustained remission was 19.5% for ETA-B and 21.0% for ETA-O. In multivariate analysis, we did not detect a significant difference in sustained remission between ETA-B and ETA-O (adjusted odds ratio 1.14, 95% CI 0.29–4.87).

Conclusion

We did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O.

Trial registration

Not applicable.